Put companies on watchlist
M1 Kliniken AG
ISIN: DE000A0STSQ8
WKN: A0STSQ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

M1 Kliniken AG · ISIN: DE000A0STSQ8 · EQS - Company News (68 News)
Country: Germany · Primary market: Germany · EQS NID: 1234639
20 September 2021 04:01PM

M1 Kliniken AG continues growth course


DGAP-News: M1 Kliniken AG / Key word(s): Expansion/Miscellaneous
M1 Kliniken AG continues growth course

20.09.2021 / 16:01
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG continues growth course

- Significant expansion of site capacities in Germany and internationally

- Sales in the "Beauty" segment well above the previous year's figures. Expected annual sales of over EUR 50 million in the Beauty segment in 2021


Berlin, 20.09.2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) sustainably continues its growth course in the third quarter of 2021. In the core market Germany alone, five new clinics have been opened in the current financial year. These clinics have been able to achieve pleasing occupancy and revenue figures already at a very early stage. With Aachen, another location is scheduled to open in October 2021. Further locations have been acquired in Würzburg and Wolfsburg.

M1 is also picking up speed abroad. Before the end of December, Brisbane will be the third location in Australia to open its doors. In The Hague, renovation work is underway for the third location in the Netherlands, which is also scheduled to open in December. Furthermore, authorisation applications for two more locations in Austria have been submitted.

The positive development is also reflected in M1's key performance figures. In the two summer months of July and August 2021, sales in the German injection clinics were 14% above the previous year's figures which were positively affected by catch-up effects from the lockdown that ended in mid-May 2020. Revenue in the international locations grew by more than 50% compared to the same two months of the previous year. For September 2021, M1 Kliniken AG has set course for a new record month. On 2 September 2021, the German specialist clinics were able to book a daily sales record. Based on the current development, M1 expects total sales in the "Beauty" sector to exceed EUR 50 million in 2021.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical area, the group of companies offers products and services with the highest quality standards. Under the "M1 Med Beauty" brand, beauty medical treatments are currently offered at more than 40 specialist centres. In this context, the M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia. With its investment in HAEMATO AG, M1 Kliniken AG is also in a position to exploit the sales and earnings potential of its treatment products in the medical aesthetic field.


Contact:
M1 Kliniken AG
Dr. Walter von Horstig, Management Board
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


20.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1234639

 
End of News DGAP News Service

1234639  20.09.2021 

fncls.ssp?fn=show_t_gif&application_id=1234639&application_name=news&site_id=boersengefluester_html
Visual performance / price development - M1 Kliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.